Targeting the PI3K/AKT/mTOR signaling pathway exhibits promising efficacy against human cancer and has been tested in various clinical trials, however, the complexity of the signaling network involving feedback loops and compensatory pathways, and intrinsic and acquired resistance limits the therapeutic success but may be addressed with combination treatments 43,44. The gene discussed is MTOR; the disease is cancer.